marketcap
Facebook
Twitter
Telegram
Report an ErrorQuarterly report 2024-Q3
added 11-12-2024
BridgeBio Pharma Balance Sheet 2011-2024 | BBIO
Annual Balance Sheet BridgeBio Pharma
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
74.6 M | 58 M | 41.9 M | 124 M | -89.8 M | -382 M | -92 M | - | - | - | - | - | - |
Long Term Debt |
446 M | 431 M | 431 M | 476 M | 91.8 M | 54.5 M | - | - | - | - | - | - | - |
Long Term Debt Current |
4.13 M | 3.68 M | 4.94 M | 3.8 M | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | 97.6 M | 534 M | 145 M | - | - | - | - | - | - |
Total Current Liabilities |
144 M | 121 M | 135 M | 95.6 M | 60.4 M | - | - | - | - | - | - | - | - |
Total Liabilities |
1.89 B | 1.87 B | 1.88 B | 597 M | 158 M | 567 M | 154 M | - | - | - | - | - | - |
Deferred Revenue |
6.1 M | 8.16 M | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-2.56 B | -1.92 B | -1.44 B | -889 M | -440 M | -171 M | -61.4 M | - | - | - | - | - | - |
Total Assets |
546 M | 623 M | 1.01 B | 704 M | 632 M | 465 M | 98 M | - | - | - | - | - | - |
Cash and Cash Equivalents |
376 M | 377 M | 394 M | 356 M | 364 M | 436 M | - | - | - | - | - | - | - |
Book Value |
-1.34 B | -1.24 B | -866 M | 106 M | 474 M | -102 M | -55.5 M | - | - | - | - | - | - |
Total Shareholders Equity |
-1.35 B | -1.25 B | -867 M | 106 M | 408 M | 377 M | 88.3 M | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet BridgeBio Pharma
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
436 M | 435 M | 435 M | 446 M | 442 M | 440 M | 436 M | 431 M | 13 M | - | 434 M | 17.4 M | 103 M | 103 M | 90.8 M | 92.4 M | 92.4 M | 92.4 M | 92.4 M | 91.8 M | 91.8 M | 91.8 M | 91.8 M | 54.5 M | 54.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
1.88 B | 1.88 B | 1.89 B | 1.89 B | 1.85 B | 1.85 B | 1.84 B | 1.87 B | 1.86 B | - | 1.85 B | 1.88 B | 1.52 B | 1.54 B | 1.48 B | 596 M | 596 M | 596 M | 596 M | 156 M | 156 M | 156 M | 156 M | 87.6 M | 87.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
11.8 M | 15.1 M | 14 M | 6.1 M | 6.59 M | 6.21 M | 6.68 M | 8.16 M | 7.52 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-2.83 B | -2.67 B | -2.6 B | -2.56 B | -2.39 B | -2.22 B | -2.06 B | -1.92 B | -1.78 B | - | -1.63 B | -1.44 B | -1.29 B | -1.13 B | -1.04 B | -889 M | -889 M | -889 M | -889 M | -440 M | -440 M | -440 M | -440 M | -179 M | -179 M | - | - | -48.7 M | - | - | - | -18.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
665 M | 794 M | 849 M | 546 M | 655 M | 504 M | 626 M | 623 M | 729 M | - | 813 M | 1.01 B | 782 M | 1.08 B | 1.09 B | 704 M | 704 M | 704 M | 704 M | 632 M | 632 M | 632 M | 632 M | 465 M | 465 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
266 M | 408 M | 475 M | 376 M | 505 M | 302 M | 407 M | 377 M | 483 M | 470 M | 372 M | 394 M | 180 M | 378 M | 471 M | 356 M | 356 M | 356 M | 356 M | 364 M | 364 M | 364 M | 364 M | 436 M | 436 M | 239 M | - | 92 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
-1.22 B | -1.08 B | -1.04 B | -1.34 B | -1.19 B | -1.35 B | -1.21 B | -1.24 B | -1.13 B | - | -1.04 B | -866 M | -736 M | -456 M | -388 M | 108 M | 108 M | 108 M | 108 M | 476 M | 476 M | 476 M | 476 M | 377 M | 377 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
-1.23 B | -1.09 B | -1.05 B | -1.35 B | -1.2 B | -1.35 B | -1.21 B | -1.25 B | -1.13 B | -1.01 B | -1.04 B | -870 M | -739 M | -464 M | -395 M | 57.9 M | 57.9 M | 57.9 M | 57.9 M | 408 M | 408 M | 408 M | 408 M | 315 M | 315 M | 204 M | 61.7 M | 85.9 M | - | - | - | 14.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency